*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」

阿思達克 11-26 09:51

*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」

Relevant Stocks

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」

Services

About Us

Agreement Statement

Market News

*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元 評級「買入」

*瑞銀上調康寧傑瑞製藥-B(09966.HK)目標價至30.3元 評級「買入」

《大行報告》瑞銀下調藥明巨諾-B(02126.HK)目標價至22元 評級「買入」

Services

About Us

Agreement Statement

*瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」

*瑞銀上調康寧傑瑞製藥-B(09966.HK)目標價至30.3元評級「買入」

《大行報告》瑞銀下調藥明巨諾-B(02126.HK)目標價至22元評級「買入」